@article {7644,
	title = {Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer},
	journal = {Journal of Clinical Oncology},
	volume = {30},
	year = {2012},
	note = {Cited By :50Export Date: 21 February 2017},
	month = {2012},
	pages = {3841 - 3847},
	abstract = {Purpose: This study compared the efficacy and safety of patupilone with those of pegylated liposomal doxorubicin (PLD) in patients with platinum-refractory or -resistant epithelial ovarian, primary fallopian tube, or primary peritoneal cancer. Patients and Methods: Patients with three or fewer prior regimens were eligible if they had received first-line taxane/ platinum-based combination chemotherapy and were platinum refractory or resistant. Patients were randomly assigned to receive patupilone (10 mg/m 2 intravenously every 3 weeks) or PLD (50 mg/m2 intravenously every 4 weeks). Results: A total of 829 patients were randomly assigned (patupilone, n = 412; PLD, n = 417). There was no statistically significant difference in overall survival (OS), the primary end point, between the patupilone and PLD arms (P = .195; hazard ratio, 0.93; 95\% CI, 0.79 to 1.09), with median OS rates of 13.2 and 12.7 months, respectively. Median progression-free survival was 3.7 months for both arms. The overall response rate (all partial responses) was higher in the patupilone arm than in the PLD arm (15.5\% v 7.9\%; odds ratio, 2.11; 95\% CI, 1.36 to 3.29), although disease control rates were similar (59.5\% v 56.3\%, respectively). Frequently observed adverse events (AEs) of any grade included diarrhea (85.3\%) and peripheral neuropathy (39.3\%) in the patupilone arm and mucositis/stomatitis (43\%) and hand-foot syndrome (41.8\%) in the PLD arm. Conclusion: Patupilone did not demonstrate significant improvement in OS compared with the active control, PLD. No new or unexpected serious AEs were identified. {\textcopyright} 2012 by American Society of Clinical Oncology.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84869109927\&doi=10.1200\%2fJCO.2011.38.8082\&partnerID=40\&md5=1daaa19302c4a3022cbf182a6553bcd7},
	author = {Colombo, N. and Kutarska, E. and Dimopoulos, M. and Bae, D.-S. and Rzepka-Gorska, I. and Bidzinski, M. and Scambia, G. and Engelholm, S.A. and Joly, F. and Weber, D. and El-Hashimy, M. and Li, J. and Souami, F. and Wing, P. and Engelholm, S. and Bamias, A. and Schwartz, P.}
}
